We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: February 14, 2008
Last Update Posted: October 29, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Sun Yat-sen University

The purpose of this study is to compare the efficacy and safety of tacrolimus vs intravenous cyclophosphamide pulses treatment for the induction therapy of LN(III,IV,V).

To compare the efficacy and safety of tacrolimus vs Azathioprine for the maintenance therapy of LN(III,IV,V).

Condition Intervention Phase
Kidney Diseases Lupus Nephritis Tacrolimus Induction Phase Maintenance Phase Drug: tacrolimus (FK506) Drug: cyclophosphamide or azathioprine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Sun Yat-sen University:

Primary Outcome Measures:
  • Remission rate [ Time Frame: 2006-2008 ]

Secondary Outcome Measures:
  • Renal function, proteinuria, relapse. [ Time Frame: 2006-2008 ]

Enrollment: 81
Study Start Date: July 2006
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
tacrolimus(fk506) treatment in induction and maintenance phase
Drug: tacrolimus (FK506)
Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
Active Comparator: 2
intravenous cyclophosphamide pulses treatment in induction phase; and Aza in the maintenance phase
Drug: cyclophosphamide or azathioprine
Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   14 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects of either sex, 14-65 years of age;
  2. Diagnosis of SLE according to the ACR criteria(1997);
  3. Kidney biopsy within the 6 months prior to first randomization with a histologic diagnosis (ISN/RPS 2003 classification of LN) class III, IV, V;
  4. Class IV LN: proteinuria >1g/24hr or Scr>115umol/L;
  5. Class III or V LN: proteinuria >2g/24hr or Scr>115umol/L;
  6. Provision of written informed consent by subject or guardian.

Exclusion Criteria:

  1. Inability or unwillingness to provide written informed consent ;
  2. Known hypersensitivity or contraindication to tacrolimus, cyclophosphamide , azathioprine, corticosteroids;
  3. Usage of immunosuppression therapy (MMF, CTX, CysA, MTX ect) for more than 1 week within 1 month prior to first randomization;
  4. Pregnancy, nursing or use of a non-reliable method of contraception;
  5. Continuous dialysis starting more than 2 weeks before randomization into the induction phase and/or continuous dialysis with an anticipated duration of more than 8 weeks;
  6. Previous kidney transplant or planted transplant;
  7. Scr > 4mg/dl (353umol/L);
  8. Active hepatitis, with liver dysfunction;
  9. Diagnosed DM;
  10. Participation in another clinic trial and/or receipt of investigational drugs within 4 weeks prior to screening .
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00615173

China, Guangdong
The 1st Affiliated Hospital, Sun Yet-sen University
Guangzhou, Guangdong, China, 510080
Sponsors and Collaborators
Sun Yat-sen University
Principal Investigator: Xue Qing Yu, MD Department of Nephrology, 1st Affiliated Hospital, Sun Yat-Sen University
Principal Investigator: Ping Fu, MD Department of Nephrology, West China Hospital of Sichuan University
Principal Investigator: Yun Hua Liao, MD Department of Nephrology, 1st Affiliated Hospital of Guangxi Medical University
Principal Investigator: Jin li Zhang, MD Department of nephrology, People's Hospital of Yunnan Province
Principal Investigator: Jian Chen, MD Department of Nephrology, Fuzhou Military General Hospital
Principal Investigator: Tan Qi Lou, MD Department of Nephrology, 3rd Affiliated Hospital of Sun Yet-Sen University
Principal Investigator: Yao zhong Kong, MD Department of Nephrology, 1st People's Hospital of Foshan
Principal Investigator: Jun zhou Fu, MD Department of Nephrology,1st People's Hospital of Guangzhou
Principal Investigator: Wei Shi, MD Department of Nephrology, People's Hospital Guangdong Provincial
Principal Investigator: Zheng rong Liu, MD Department of Nephrology, Nanfang Hospital of Southern Medical University
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Xueqing Yu, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT00615173     History of Changes
Other Study ID Numbers: SYSU-PRGLN-001
First Submitted: February 1, 2008
First Posted: February 14, 2008
Last Update Posted: October 29, 2008
Last Verified: October 2008

Keywords provided by Sun Yat-sen University:
lupus nephritis

Additional relevant MeSH terms:
Kidney Diseases
Lupus Nephritis
Urologic Diseases
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Calcineurin Inhibitors
Enzyme Inhibitors
Antimetabolites, Antineoplastic